Alzheimer’s Awareness Month: A Revolutionary New Test for Alzheimer’s Disease That Takes Just Two Minutes

This month, i.e., November is Alzheimer’s Disease Awareness Month. Many people still believe that dementia is normal aging. This is why it’s so important to create awareness campaigns like World Alzheimer’s Month that change perceptions and increase public knowledge about dementia and Alzheimer’s.

According to a report by Market.us,” The worldwide market for Alzheimer’s Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of roughly 6.8% over the next ten years. It will reach USD 7.80 billion by 2032, from USD 4.04 billion in 2022.”

The number of people suffering from Alzheimer’s disease (AD) dementia, which is primarily caused by dementia, is expected to increase in a pair. AD is responsible for 60% and 80% of all dementia cases. An estimated 5-7 million people are diagnosed each year with AD. Alzheimer’s disease is the sixth leading cause of death in the United States and the leading cause.

Anurag Sharma, a senior research analyst at Market.us said,” For optimal intervention success, early detection is key. It also helps in counseling patients and their families, enrolling in clinical trials, and deciding which patients will benefit from future disease-modifying therapy.” 

The Market.us research team has conducted a thorough qualitative and quantitative analysis. The analysis covers Alzheimer’s Disease Therapeutics and Diagnostics Market and its advancements across different industry verticals as well as regions. 

Although there has been extensive research into AD, diagnosis is made present through clinical assessment, neuroimaging, biomarker detection from positron emission imaging, or cerebrospinal Fluid Examination. Patients are faced with high costs and late diagnosis. 

Limited treatment options are available due to the uncertainty, failures, and discontinuation of the clinical trials of Alzheimer’s drugs. This raises the cost of research and development. Market growth is likely to be slowed by this. For example, Amgen Inc., Novartis AG, and Novartis AG terminated their Phase 2 clinical trial of CNP520 (umibecestat), a BACE1 inhibitor of Alzheimer’s, in July 2019 due to a lack of desired results.

Most tests require large quantities of fluid and complex procedures. They can also take several hours to complete. To tackle this issue, research from Swansea University in the United Kingdom developed a new and innovative diagnostic platform with the help of AI-ML. The notable feature of this platform is that it can provide results within 2 minutes.

Diagnosis of Alzheimer’s often relies upon measuring and analyzing the Amyloid beta and tau protein in cerebrospinal fluid, which is often interlinked with the onset of it. In order to diagnose, one such method is to calculate the concentration level of different proteins in biofluids like blood, saliva, and synovial joint.

The exact causes of Alzheimer’s aren’t well understood yet, but the CDC lists major predictors that increase your risk of developing the condition. The causes could range from family history to poor heart health, brain injury, and exposure to toxic substances. 

Now, even picking your nose might be one of the reasons one needs to be wary of. A recent study by Griffith University in Australia performed an experiment on rats with a bacteria named Chlamydia pneumonia, a respiratory tract pathogen.

By the results, they concluded that picking and plucking the nose might not be a good idea. This is because when someone picks the nose, it damages the internal tissue, thus creating a clear way to the brain. This leads to the bacteria Chlamydia pneumonia invading the central nervous system. The bacteria are responsible for the late-stage onset of Alzheimer’s.

Some limitations include the fact that the supporting research has been done on mice, and the effects may or may not apply to humans. But these findings are certainly worth further investigation. It could improve our understanding of how Alzheimer’s develops, which is still a mystery.